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Abstract
Background: The tumor microenvironment has complex effects in cancer pathophysiology that are not fully
understood. Most cancer therapies are directed against malignant cells specifically, leaving pro-malignant signals
from the microenvironment unaddressed. Defining specific mechanisms by which the tumor microenvironment
contributes to breast cancer metastasis may lead to new therapeutic approaches against advanced breast cancer.
Methods: We use a novel method for manipulating three-dimensional mixed cell co-cultures, along with studies
in mouse xenograft models of human breast cancer and a histologic study of human breast cancer samples, to
investigate how breast cancer-associated fibroblasts affect the malignant behaviors of breast cancer cells.
Results: Altering fibroblast Tiam1 expression induces changes in invasion, migration, epithelial-mesenchymal
transition, and cancer stem cell characteristics in associated breast cancer cells. These changes are both dependent on
fibroblast secretion of osteopontin and also long-lasting even after cancer cell dissociation from the fibroblasts, indicating
a novel Tiam1-osteopontin pathway in breast cancer-associated fibroblasts. Notably, inhibition of fibroblast osteopontin
with low doses of a novel small molecule prevents lung metastasis in a mouse model of human breast cancer metastasis.
Moreover, fibroblast expression patterns of Tiam1 and osteopontin in human breast cancers show converse changes
correlating with invasion, supporting the hypothesis that this pathway in tumor-associated fibroblasts regulates breast
cancer invasiveness in human disease and is thus clinically relevant.
Conclusions: These findings suggest a new therapeutic paradigm for preventing breast cancer metastasis. Pro-malignant
signals from the tumor microenvironment with long-lasting effects on associated cancer cells may perpetuate the
metastatic potential of developing cancers. Inhibition of these microenvironment signals represents a new therapeutic
strategy against cancer metastasis that enables targeting of stromal cells with less genetic plasticity than associated
cancer cells and opens new avenues for investigation of novel therapeutic targets and agents.
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Background
The tumor microenvironment plays an important role in
tumor evolution and the reciprocal signals between cancers
and the surrounding microenvironments are beginning to
be elucidated [1, 2]. There is growing evidence that the
stromal microenvironment around cancer cells influences
the growth, invasiveness, and metastatic behavior of cancer
cells, and may be a factor in therapeutic response. Tumor-
associated stroma contains various cell types and mole-
cules secreted into the extracellular matrix, and the list of
factors that participate in the co-evolution of tumors with
tumor-associated stroma is growing [3]. Of note, fibro-
blasts are the predominant cell type in stromal connective
tissue, contributing to deposition and maintenance of col-
lagen, basement membrane and paracrine growth factors.
There is emerging evidence that fibroblasts may actively
function in the induction of cancers [4], and that tumor
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invasion is influenced by external signals from the tumor-
associated stroma [5, 6]. Specific mechanisms underlying
how the tumor microenvironment contributes to breast
cancer metastasis are not yet fully understood.
We have investigated whether the Rac exchange factor
Tiam1 in the human breast cancer microenvironment has
a role in regulating tumor invasion and metastasis. This
question initially arose from a paradox in understanding
Tiam1. Tiam1 is a ubiquitous protein involved in a number
of signaling pathways with varied functional outcomes
depending on cellular context [7–13]. Much of the work
on Tiam1 has focused on its role within cancer cells, and
Tiam1 expression in tumor cells is required for facilitating
tumor growth [14–17]. However, in mice genetically lack-
ing Tiam1, the tumors that do develop are more invasive,
conceptually inconsistent with the requirement for Tiam1
for tumor growth and functionally inconsistent with how
human tumors behave clinically. We therefore hypothe-
sized that decreased tumor growth in these mice is due to
Tiam1 deficiency in the tumor cells, while the increased
tumor invasion is due to Tiam1 deficiency in the tumor
stroma, specifically in the fibroblasts. In epithelial cells
Tiam1 expression is Wnt-responsive and regulated by
post-translational events, including phosphorylation and
proteolysis [14, 18–20]. Many groups have investigated
Tiam1 expression in different tumor cell models and
human tumor specimens [14, 21–27]. However, we have
chosen to focus on the role of Tiam1 in tumor-associated
stroma. Using three different experimental systems, includ-
ing three-dimensional (3D) mixed cell spheroid co-cultures
of mammary epithelial and fibroblast cells, a 3D orga-
notypic culture model of human skin tumors, and a
mouse xenograft model of human breast cancer, we
recently reported that Tiam1 deficiency in tumor-asso-
ciated fibroblasts induces increased invasion of the
associated epithelial or tumor cells and increased tumor
metastasis [28].
We have also found that the glycoprotein osteopontin
(OPN) is a major mediator of the effects of fibroblast
Tiam1 expression in fibroblasts undergoing stress-induced
senescence [29]. Changes in fibroblast Tiam1 expression
induce converse changes in OPN transcription and pro-
tein secretion. Stress-induced senescence in fibroblasts
induces decreased fibroblast Tiam1 and increased OPN
expression, and subsequently increased invasion of co-
cultured mammary epithelial cells. OPN is a phosphory-
lated glycoprotein secreted by multiple cell types, both
malignant and non-malignant [30]. It is detectable in
extracellular matrix, tissues, and body fluids, and is impli-
cated in several pathophysiologic processes, including
tumor progression (reviewed in [31]). We therefore inves-
tigated the hypothesis that the Tiam1-OPN pathway in
mammary fibroblasts influences the invasive and meta-
static behavior of breast cancers.
Methods
Cell culture
The parental reduction mammary fibroblast (RMF) fibro-
blast line and the human breast cancer cell lines were kind
gifts from Dr. Charlotte Kuperwasser, Tufts University. Der-
ivation of the stable protein-silencing or protein-expressing
sublines has been described previously, as follows:
Tiam1-deficient shTiam-RMF and retroviral hairpin
control RMF (C-RMF) [28];
Tiam1-overexpressing (+Tiam) RMF, pBabe vector
control RMF, Tiam1 and OPN-deficient shTiam-OPN
RMF and the double retroviral-lentiviral control [29];
human breast cancer cells SUM1315 and SUM159 [32].
Methods indicated, as previously described, are in-
cluded in more detail in the supplementary material
(see Additional file 1).
Spheroid co-culture
Co-cultures were established as previously described
[33]. Where indicated, the following were incorporated
into Matrigel and culture medium: 667 ng/mL anti-OPN
antibody (Santa Cruz Biotechnology, Dallas, TX, USA);
667 ng/mL isotypic immunoglobulin G (IgG) control
antibody; 75 nM Agelastatin A (AgelA); 750 uM cyclo-
phosphamide; 1 nM docetaxel; 8 nM doxorubicin. AgelA
was synthesized as previously described [34]. Stock solu-
tions (1 mM) were stored in methanol at -20 °C.
Isolation of cells from spheroid co-culture
Cells were isolated from 3D co-cultures and cancer cells
were separated from fibroblasts as described previously
to derive post-co-culture (PCC) cell populations [33].
Flow cytometry was used to demonstrate purity of cells
isolated post-co-culture to greater than 99 % cancer cells
using fluorescent markers (RMFs with green fluorescent
protein (GFP), cancer cells with or without pCherry).
Growth curves
RMF or SUM1315 cells were seeded at 3 × 105 cells per
100 cm culture dish in appropriate culture medium in
the absence or presence of AgelA at final indicated con-
centrations, and passed every 2 days (3 × 105 cells per
passage). Total number of cells in each dish was calcu-
lated as the number of cells in the dish at each time
point corrected for the fractional passages.
Immunoblotting
Immunoblotting was performed as previously described
[28]. Antibodies were obtained from the following sources:
Tiam, GAPDH, Fibronectin, Twist (Santa Cruz Biotechnol-
ogy); Snail, Slug, E-cadherin, N-cadherin (Cell Signaling
Technology, Danvers, MA, USA).
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Transwell migration assay
Standard transwell migration assays were performed as
previously described [29]. For experiments testing the
differential effect of OPN antibody against cancer cells
compared with fibroblasts, SUM1315 cells were seeded
in the top wells, and control hairpin vector (shC) or
Tiam1-deficient RMF (shT) cells were seeded in the bot-
tom wells as indicated (2 × 104 cells/well for each cell
type). Some SUM1315 were incubated with control IgG
or OPN antibody (6.7 μg/mL) for 16 h in culture prior
to assay as well as during the 5-h migration assay, as in-
dicated (top well Ab). RMF were seeded into bottom
wells 16 h before assay to establish conditioned medium
and similarly incubated with indicated antibodies before
and during the assay (bottom well Ab).
Tumorsphere assays
Tumorsphere formation was assessed as previously
described [32].
Flow cytometry
Flow cytometry was performed as previously described
[32].
Real-time PCR
Isolation of ribonucleic acid (RNA) and quantitative reverse
transcriptase polymerase chain reaction (RT-PCR) were
performed as previously described [29], using the following
primer pairs:
Snail, 5′-AATCGGAAGCCTAACTACAGCG-3′
(sense), 5′-GTCCCAGATGAGCATTGGCA-3′
(antisense);
Slug, 5′-AAGCATTTCAACGCCTCCAAA-3′
(sense), 5′-AGGATCTCTGGTTGTGGTATGAC-3′
(antisense);
Twist, 5′-GTCCGCAGTCTTACGAGGAG-3′
(sense), 5′-GCTTGAGGGTCTGAATCTTGCT-3′
(antisense);
Fibronectin, 5′-CAGTGGGAGACCTCGAGAAG-
3′ (sense), 5′-TCCCTCGGAACATCAGAAAC-3′
(antisense);
N-Cadherin, 5′-TCCTACTGGACGGTTCGCCA-3′
(sense), 5′-TTGCAGTTGACTGAGGCGGG-3′
(antisense);
E-Cadherin, 5′-CCCACCACGTACAAGGGTC-3′
(sense), 5′-ATGCCATCGTTGTTCACTGGA-3′
(antisense);
GAPDH, 5′-CTGCACCACCAACTGCTTAG-3′
(sense), 5′-TTCAGCTCAGGGATGACCTT-3′
(antisense);
Tiam1, 5′- AAGACGTACTCAGGCCATGTCC-3′
(sense), 5′-GACCCAAATGTCGCAGTCAG-3′
(antisense);
OPN, 5′-GCCATACCAGTTAAACAGGC -3′
(sense), 5′- GACCTCAGAAGATGCACTAT -3′
(antisense).
Human breast cancer xenograft models
Primary tumors
PCC-SUM1315 cells were isolated from co-cultures with
control, Tiam1-deficient, or Tiam1-overexpressing fibro-
blasts as indicated. PCC-non-fluorescing SUM1315 cells
were further purified from GFP-expressing RMFs by
flow cytometry, suspended in a mixture of Matrigel and
SUM1315 culture medium (1:3 ratio), and injected into
fourth inguinal mammary glands in a 35 μL volume into
NOD-SCID mice (The Jackson Laboratory, Bar Harbor,
ME, USA).
Passaged tumors were established as previously
described [32].
Immunohistochemical staining of human tumor samples
Immunohistochemistry was performed on the Ventana
Benchmark XT (Ventana Medical Systems, Inc., Tucson,
AZ, USA) using the following antibodies: Tiam1, Santa
Cruz sc-872; osteopontin, Abcam (Cambridge, MA,
USA) ab33046. Assessment of Tiam1 and osteopontin
staining in human breast cancer tissue was performed
by two board-certified pathologists, one of whom is an
experienced breast pathologist. The presence or absence
of staining in peritumoral fibroblasts within 100 microns
of the interface between tumor epithelium and stroma
was performed by routine light microscopy. Identifica-
tion of fibroblasts was primarily by morphologic criteria
as the specificity of immunohistochemical markers for
fibroblasts is poor. Therefore exclusion of cells that may
be confused with fibroblasts was achieved by staining
parallel sections with immunostains for endothelium
(CD31) and inflammatory cells (CD68, CD45). The
assessment of Tiam1 and osteopontin expression was
determined by the presence or absence of stained
fibroblasts and, to a lesser degree, by the intensity of
the staining. Given variable fibroblast density among
different breast cancer samples, the relative occurrence
of stained fibroblasts within the 100 micron perimeter
adjacent to pure ductal carcinoma in situ (DCIS) and
pure invasive carcinoma was determined using a mi-
crometer eyepiece. For both Tiam1 and OPN, greater
than 50 % positive fibroblasts was counted as overex-
pression, and less than 10 % positive fibroblasts was
counted as decreased expression. The average percent-
age of Tiam1-positive fibroblasts was 80.8 % for DCIS
and 5.0 % in invasive carcinoma. The average percent-
age of OPN-positive fibroblasts was 6.9 % in DCIS and
77.5 % in invasive carcinoma.
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Approval for studies on animals and archived material
from human subjects
All animal studies were conducted under approval of the
Tufts University and Tufts Medical Center Institutional
Animal Care and Use Committee in accordance with
institutional and national regulatory standards (Tufts
University and Tufts Medical Center Institutional
Animal Care and Use Committee Protocol number
B2013-51, PI Kuperwasser). Archived de-identified
human breast cancer samples were obtained from the
Tufts Cancer Center Repository, with waiver of need
for informed consent granted by the Tufts Medical
Center Institutional Review Board (IRB number 9138,
certification of Exempt Status, PI Buchsbaum).
Results
To assess whether Tiam1 expression in mammary fibro-
blasts affects invasiveness of breast cancer cells in vitro,
we adapted a 3D co-culture model of fibroblast and
epithelial cell lines in extracellular matrix [35]. We have
shown that co-culture of immortalized human mammary
epithelial cells (HMECs) and immortalized human mam-
mary fibroblasts (RMFs) in a Matrigel plug leads to
assembly of 3D spheroid structures with fibroblasts clus-
tering in the interior of the spheroid and epithelial cells
arranged on the exterior of the spheroid [28]. Under
conditions promoting invasion, the epithelial cells form
multicellular outgrowths projecting out into the matrix.
Invasiveness can be measured by counting the number
of epithelial projections per spheroid [29]. We found
that co-culture of several different breast cancer cell
lines with RMFs leads to formation of similar spheroidal
structures (not shown). In this study we tested the effect
of manipulating fibroblast Tiam1 expression on the
invasiveness of two aggressive breast cancer cell lines,
SUM1315 and SUM159 [32] (Fig. 1). When cultured
with control RMFs, most spheroids had 0–1 projection,
but when cultured with RMFs with stable silencing of
Tiam1 (shTiam1) there was a significant increase in the
number of spheroids exhibiting increased numbers of
projections. In contrast, spheroids with 0–1 projection
increased and spheroids with higher numbers of projections
Fig. 1 Effect of fibroblast Tiam1 expression on breast cancer cell invasion into co-culture matrix and migration of post-co-culture cells. a Number
of projections/spheroid for SUM159 breast cancer cells and indicated mammary fibroblasts in 3D mixed cell spheroid co-culture. For fibroblasts:
shC and shTiam refer to control silencing retroviral hairpin vector and Tiam1-silencing hairpin vector respectively; +C and + Tiam refer to pBabe
control vector and pBabe-Tiam1 overexpression vector respectively. Results show number of spheroids with indicated number of projections as
percent of total spheroids. At least 150 spheroids were counted for each condition. b Similar experiment as in A using SUM1315 breast cancer
cells. At least 100 spheroids were counted for each condition. For A and B, results represent at least duplicate experiments. c Transwell migration
of SUM159 after isolation from mixed cell spheroid co-cultures with indicated mammary fibroblasts. d Similar to C using SUM1315 breast cancer
cells. For C and D, cell counts were averaged across nine high-power fields for biologic triplicates; results represent duplicate experiments. For
fibroblasts in all experiments, shC= control silencing hairpin pSuperior vector; shTiam1= Tiam1 silencing; +C= pBabe overexpression vector; +Tiam= Tiam1
overexpression vector
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decreased when cultured with RMFs overexpressing Tiam1.
(Tiam1 expression in engineered RMFs is shown in Figure
S1A in Additional file 2. All supplemental figures are in-
cluded in the supplementary material [see Additional file 2]).
This suggests that increased Tiam1 expression in mam-
mary fibroblasts decreases invasiveness, and decreased
Tiam1 expression increases invasiveness, in associated
human breast cancer lines in a 3D environment.
In order to further assess the effects of mammary fibro-
blasts on associated human breast cancer cells, we derived
a simple method for isolating enriched cancer cell popula-
tions after exposure in 3D co-culture [33], termed post-
co-culture (PCC) cells. We have found that the effects of
exposure to fibroblast in co-culture persist in PCC cancer
cells for weeks after isolation, allowing for further study.
We first tested the effect of exposure to Tiam1-modulated
fibroblasts on migration of PCC breast cancer cells. Ex-
posure to Tiam1-deficient fibroblasts increased migration
across a perforated transwell, while exposure to Tiam1-
overexpressing fibroblasts decreased migration (Fig. 1c, d).
Tiam1 expression in fibroblasts modulates EMT in breast
cancer cells isolated from 3D co-cultures
Since exposure to Tiam1-manipulated fibroblasts induced
changes in invasion and migration in associated breast
cancer cells, we then tested whether markers of epithelial-
mesenchymal transition (EMT) in PCC-SUM1315 cells
were also affected (Fig. 2). Exposure to Tiam1-deficient
fibroblasts induced increases in the EMT profile, with a
marked increase in Snail transcription (Fig. 2a). Smaller
increases were seen in Slug, Twist, Fibronectin and N-
cadherin, while E-cadherin transcription was decreased.
Conversely, exposure to Tiam1-overexpressing fibroblasts
decreased the EMT profile, with a marked decrease in
Snail and Fibronectin, smaller decreases in Slug and Twist,
and marked increase in E-cadherin transcription (Fig. 2b).
Similar directional changes in EMT gene transcription
profiles were found for SUM159 after exposure to Tiam1-
deficient or Tiam1-overexpressing fibroblasts (Figure S2
in Additional file 2). Changes in gene transcription were
paralleled by corresponding changes in protein expression
(Fig. 2c). Thus exposure to Tiam1-altered fibroblasts in
3D induced changes in EMT consistent with induced
changes in invasion and migration.
Tiam1 expression in fibroblasts modulates markers of
stem cell populations in breast cancer cells isolated from
3D co-cultures
EMT has been associated with cancer stem cell popula-
tions [36]. We therefore investigated whether Tiam1 ex-
pression in mammary fibroblasts would affect cancer stem
cell populations in associated breast cancer cells. We first
Fig. 2 Effect of Tiam1 expression in fibroblasts on EMT in SUM1315 breast cancer cells isolated from 3D co-cultures. a Quantitative RT-PCR for
mRNA of indicated proteins relative to GAPDH control from SUM1315 breast cancer cells isolated from 3D spheroid co-culture with control or
Tiam1-deficient mammary fibroblasts. b Quantitative RT-PCR for mRNA of indicated proteins from SUM1315 breast cancer cells isolated from 3D
spheroid co-culture with control or Tiam1-overexpressing mammary fibroblasts. For A and B, results represent mean +/- SD for duplicate
experiments; *Indicates p < 0.05 by t test. c Immunoblots from cell lysates of breast cancer cells derived as in A and B; biologic duplicates
shown for each condition. Sn = Snail, Sl = Slug, Tw = Twist, Fn = Fibronectin, Ncad = N-cadherin, Ecad = E-cadherin
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determined whether the ability to nucleate a tumorsphere
under low-adherence conditions was affected. Consistently,
exposure to Tiam1-deficient fibroblasts induced increased
numbers of tumorspheres in both SUM159 and SUM1315
PCC cells (Fig. 3a, b). Exposure to Tiam1-overexpressing
fibroblasts led to decreased tumorsphere formation. While
tumorsphere numbers were affected, tumorsphere size was
not (Figure S1B in Additional file 2).
We also used flow cytometry to assess cancer stem cell
populations in PCC cancer cells. The CD44+/CD24-/ESA+
subpopulation has been identified as being significantly
enriched in the breast cancer stem cell population [32]. For
both the SUM159 and SUM1315 lines, this population rep-
resented a small fraction of the cells after going through
3D co-culture with fibroblasts. However, exposure to
Tiam1-deficient fibroblasts consistently led to approximate
doubling of the CD44+/CD24-/ESA+ population, while
exposure to Tiam1-overexpressing fibroblasts consistently
led to a twofold decrease in the CD44+/CD24-/ESA+ popu-
lation (Fig. 3c, d, and Figure S1C in Additional file 2). Thus
the results of both tumorsphere assay and flow cytometry
of cell surface markers suggested that Tiam1 expression in
mammary fibroblasts modulates cancer stem cell-like
populations in these breast cancer cell lines.
Tiam1 expression in fibroblasts modulates breast cancer
stem cell populations in vivo
The defining characteristics of cancer stem cells are the
ability to initiate tumors in vivo and to maintain self-
renewal. We therefore tested the ability of SUM1315 cells
to initiate tumors in a mouse xenograft model after expos-
ure to mammary fibroblasts in 3D co-culture. Xenograft
implantations were established using PCC-SUM1315
breast cancer cells. Exposure to Tiam1-deficient fibroblasts
significantly enhanced the ability of PCC-SUM1315 cells to
initiate tumors (Table 1A). Conversely, exposure to Tiam1-
overexpressing fibroblasts significantly impaired the ability
of PCC-SUM1315 to initiate tumors.
Self-renewal capability was tested by passage of primary
tumors to secondary recipients. Three pairs of primary
tumors arising from SUM1315 post-co-culture with control
RMF or Tiam1-deficient RMF, matched for size, were
Fig. 3 Effect of Tiam1 expression in fibroblasts on tumorsphere formation and CD44+/CD24-/ESA+ populations in breast cancer cells isolated
from 3D co-cultures. a SUM159 breast cancer cells isolated from 3D co-cultures with indicated mammary fibroblasts were cultured at low density
under ultra-low adherence conditions and tumorspheres were quantitated under light microscopy. b Similar experiment as in A using SUM1315
breast cancer cells. c Populations of SUM159 breast cancer cells were quantified by flow cytometry for expression of indicated cell surface markers
using fluorophor-conjugated antibodies after isolation from 3D co-cultures with indicated fibroblasts. d Similar experiment as in C using SUM1315
cells. For A-D, results represent duplicate experiments, each with biologic triplicates
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passaged into secondary recipients. Co-culture with Tiam1-
deficient fibroblasts led to primary tumors with significantly
greater ability to give rise to secondary tumors at all im-
plantation doses, particularly at low cell numbers (Table 1B).
Thus varying Tiam1 expression in mammary fibroblasts
modulated cancer stem cell properties in associated breast
cancer cells.
The effects of Tiam1-deficient fibroblasts on SUM1315
breast cancer cell invasion, migration, and cancer stem
cell-like populations are dependent on fibroblast
osteopontin
We have found that stress-induced senescence induces
decreased Tiam1 expression in mammary fibroblasts
and that Tiam1 decrease in fibroblasts is associated
Table 1 Effect of fibroblast Tiam1 on tumor-initiating ability of post-co-culture breast cancer cells in primary (A) and passaged (B)
mouse xenografts
b
a
Results are shown as: #tumor-bearing mice/total mice (#tumors/#xenograft implantations)
P values calculated by t test
PCC post-co-culture, RMF reduction mammary fibroblast
A. Primary xenografts were established with SUM1315 breast cancer cells under conditions of limiting dilution after isolation from 3D co-cultures with indicated
mammary fibroblasts. B. Secondary passaged xenografts were established in serial dilution with single cell suspensions of primary tumors established in A, taken
from the 106 cell implantation and matched for size and weight
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with increased expression and secretion of fibroblast OPN
[29]. We therefore asked whether the effects of Tiam1-
deficient fibroblasts on breast cancer cell behavior were
dependent on fibroblast OPN. We first tested the effect of
silencing OPN expression in mammary fibroblasts (Fig. 4).
(OPN transcription in engineered RMFs is shown in Figure
S1D in Additional file 2.) Co-culture of SUM1315 with fi-
broblasts deficient in both Tiam1 and OPN completely ab-
rogated the increased invasiveness induced by co-culture
with Tiam1-deficient fibroblasts (Fig. 4a). Concordantly,
PCC SUM1315 isolated from co-cultures with fibroblasts
deficient in both Tiam1 and OPN also displayed decreased
migration, tumorsphere formation, and CD44+/CD24-/
ESA+ populations (Fig. 4b–d), compared with SUM1315
isolated from co-cultures with Tiam1-deficient fibroblasts.
We also tested the ability of an OPN antibody to block
the effects of Tiam1-deficient fibroblasts in these assays.
Incorporation of an OPN antibody into the matrix and
medium of the co-cultures led to a significant decrease in
numbers of invading projections, independent of the
Tiam1 expression of the co-cultured RMFs (Fig. 4e). As
OPN is secreted by multiple cell types, including cancer
cells, we investigated whether the incorporated OPN anti-
body was primarily affecting fibroblast-derived OPN or
SUM1315-derived OPN. We found that OPN transcrip-
tion is significantly less in SUM1315 cells than in RMF
cells (Figure S3A in Additional file 2). We then tested the
effect of OPN inhibition on migration of SUM1315 cells
using differential incorporation of OPN antibody against
SUM1315 cells or RMF cells (Figure S3B in Additional
file 2). Overall SUM1315 migration was increased to-
ward Tiam1-deficient fibroblasts (darker bars). Incorpor-
ating OPN antibody against SUM1315 cells (in the
SUM1315 culture and in the top well) had no effect on
SUM1315 migration. Incorporating OPN antibody against
RMF cells (in the bottom well) significantly blocked
SUM1315 migration. These results suggest that the major
effect of the OPN antibody in these co-cultures is against
fibroblast-derived OPN, and are consistent with our find-
ings that OPN silencing in RMF is sufficient to block all of
the effects of RMF Tiam1 silencing on associated
SUM1315 cancer cells (Fig. 4a–d). Correspondingly,
SUM1315 isolated from co-cultures incorporating OPN
antibody displayed decreased migration, tumorsphere for-
mation, and CD44+/CD24-/ESA+ populations (Fig. 4f–h).
Taken together, these findings suggest that the effects of
fibroblast Tiam1 deficiency on SUM1315 breast cancer
cell behavior are dependent on fibroblast OPN.
OPN inhibition during co-culture of SUM1315 breast cancer
cells and mammary fibroblasts prevents development of
lung metastases in mice
Tiam1-deficient fibroblasts promote metastasis in a mouse
xenograft co-implantation model of human breast cancer
[28]. Given the results above of OPN inhibition by gene
silencing or antibody in vitro, we tested the effects of a
chemical inhibitor of OPN in blocking the effects of
Tiam1-deficient RMF in an accelerated in vivo model of
breast cancer metastasis. Agelastatin A (AgelA) is a bromi-
nated oroidin alkaloid originally of marine origin, and syn-
thetic AgelA inhibits OPN transcription and expression
[37]. One of our laboratories has developed a concise enan-
tioselective solution for the total chemical synthesis of
AgelA [34, 38]. We therefore tested the ability of synthe-
sized AgelA to block the effects of Tiam1-deficient fibro-
blasts on SUM1315 breast cancer cells in our systems.
We first tested the cytotoxicity of AgelA in a proliferation
assay of RMFs in 2D culture (Figure S4a in Additional file
2). Twenty-five, 50, and 100 nM AgelA had no statistically
significant effect on cell proliferation. Notable decreases in
proliferation were seen at concentrations higher than 100
nM, consistent with prior reports of cytotoxicity [37]. Simi-
larly, treatment with AgelA 75 nM had no direct effect on
SUM1315 proliferation (Figure S4b in Additional file 2).
We then tested whether AgelA at non-cytotoxic concen-
trations could block the induction of OPN expression by
vitamin D, a known inducer of OPN transcription [39].
Vitamin D induced an almost twofold increase in OPN
transcription, which was blocked by concurrent treatment
with increasing doses of AgelA (Figure S4c in Additional
file 2). Notably, 50–100 nM of AgelA prevented any
significant vitamin D-induced increase in OPN transcrip-
tion. AgelA treatment had no effect on Tiam1 expression
(not shown).
We next tested the effect of incorporating AgelA into
our co-cultures and post-co-culture assays. Increasing
doses of AgelA in the co-culture matrix and medium led
to decreasing SUM1315 invasion into 3D matrix (Figure
S5a in Additional file 2). Notably, 100 nM AgelA almost
completely abolished the increased invasiveness induced
by Tiam1-deficient fibroblasts, compared with vehicle
alone. In the biologic assays of PCC-SUM1315, we also
found corresponding decreases in migration, tumorsphere
formation, and CD44+/CD24-/ESA+ populations (Figures
S5b, S6a-b in Additional file 2).
We also assessed whether AgelA treatment could have
direct functional effects on breast cancer cells by assaying
SUM1315 cells grown alone under standard 2D tissue cul-
ture conditions. As noted above (Figure S3 in Additional
file 2), there is very little OPN transcription in SUM1315
cells compared with RMF cells, and this was not signifi-
cantly affected by AgelA treatment (not shown). Consistent
with this, we found that treatment with AgelA 75 nM had
no effect on migration, tumorsphere formation, or
CD44+/CD24-/ESA+ populations of SUM1315 in 2D cul-
ture (not shown). The effects of AgelA on the behavior of
SUM1315 depended on exposure to RMF in 3D mixed cell
co-cultures.
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Fig. 4 (See legend on next page.)
Xu et al. Breast Cancer Research  (2016) 18:14 Page 9 of 15
In comparative experiments, we also investigated
whether treatment with chemotherapy would have
similar effects as AgelA on invasion, migration, and
cancer stem cell population. We first determined maximal
tolerated concentrations for doxorubicin, docetaxel, and
cyclophosphamide that did not affect cell growth, arriving
at final concentrations of doxorubicin 0.8 nM, docetaxel
0.95 nM, and cyclophosphamide 1000 nM. We then estab-
lished co-cultures with SUM1315 and either control or
Tiam1-deficient fibroblasts as detailed above, incorporating
each chemotherapeutic agent or control media into the co-
cultures. Co-culture with Tiam1-deficient fibroblasts
induced increased SUM1315 invasion into the 3D matrix
(Figure S7a in Additional file 2). However, no chemothera-
peutic agent prevented increased invasiveness, in contrast
to AgelA. Similarly, no chemotherapeutic agent prevented
increased PCC SUM1315 migration, tumorsphere forma-
tion, or CD44+/CD24-/ESA+ populations induced by
exposure to Tiam1-deficient fibroblasts (Figures S7b, S8a-b
in Additional file 2).
We therefore tested the effects of AgelA in an acceler-
ated model of metastasis in a mouse xenograft model
(Fig. 5). We established co-cultures with SUM1315 and
control or Tiam1-deficient RMF, incorporating either
75nM AgelA or vehicle (methanol [MeOH]). PCC-
SUM1315 from each co-culture were implanted into the
fourth mammary fat pads of immune-deficient mice. All
mice developed palpable primary tumors within 5 weeks,
with similar tumor growth. In contrast, there was a clear
difference in metastatic burden in the lungs, as assessed
by immunohistochemistry (IHC). Implantation of PCC-
SUM1315 exposed to control RMF and vehicle led to a
low level of lung metastasis. Implantation of PCC-
SUM1315 exposed to Tiam1-deficient RMF and vehicle
led to a high level of lung metastasis (three mice with
foci that were too numerous to count). In contrast, in-
corporation of AgelA into the co-cultures completely
abolished the lung metastases, even though primary
tumor growth was unaffected.
In human breast cancer-associated fibroblasts, Tiam1
expression varies inversely with cancer invasiveness,
while OPN expression varies directly with cancer
invasiveness
Finally, to evaluate the possible role of the fibroblast
Tiam1-OPN pathway in human cancer, we investigated
the expression of Tiam1 and OPN in fibroblasts associ-
ated with human breast cancers using IHC (Fig. 6). In a
pilot study we found Tiam1 protein expression to be read-
ily detectable in cancer-associated fibroblasts in 15 of 17
cases of DCIS (ductal carcinoma in situ), but decreased in
cancer-associated fibroblasts in 19 cases of invasive can-
cers (p < 0.001). In an expanded study, 36 independent
surgical specimens from 26 individual cases of breast can-
cer (invasive and/or in situ ductal carcinomas) had tissue
available for IHC for Tiam1 and/or OPN expression. In
20 areas of invasive ductal carcinoma, cancer-associated
fibroblasts showed increased cytoplasmic OPN expres-
sion and decreased Tiam1 expression. In 19 areas of
DCIS, cancer-associated fibroblasts showed decreased
expression of OPN and increased cytoplasmic expres-
sion of Tiam1. Clinical characteristics of the tumors are
shown in Table S1 (see Additional file 3). These findings
were independent of tumor grade, lymph node status,
estrogen receptor (ER) and progesterone receptor (PR)
expression. Of note, while human epithelial receptor 2
(HER2) expression ranged from 0 to 3+ by IHC staining,
there were no cases of HER2 amplification by fluores-
cence in situ hybridization (FISH) in this cohort. Ex-
pression of Tiam1 and OPN in the tumors themselves
did not correlate with invasiveness. These results show
that expression of Tiam1 and OPN in breast cancer-
associated fibroblasts are inversely related to each other
and correlate with tumor invasiveness.
(See figure on previous page.)
Fig. 4 OPN inhibition prevents effects of Tiam1-deficient fibroblasts on breast cancer cell invasion, migration, and cancer stem cell-like populations. a-d In-
hibition with OPN silencing. a Number of projections/spheroid for SUM1315 breast cancer cells and indicated mammary fibroblasts in 3D mixed cell spher-
oid co-culture. At least 130 spheroids were counted for each condition; results represent duplicate experiments. b Transwell migration of SUM1315 after
isolation from mixed cell spheroid co-cultures with indicated mammary fibroblasts. Cell counts were averaged across nine high-power fields
for biologic triplicates. c SUM1315 breast cancer cells isolated from 3D co-cultures with indicated mammary fibroblasts were cultured at low
density under ultra-low adherence conditions and tumorspheres were quantitated under light microscopy. d Populations of SUM1315 breast
cancer cells were quantified by flow cytometry for expression of indicated cell surface markers using fluorophor-conjugated antibodies after
isolation from 3D co-cultures with indicated fibroblasts. For fibroblasts in A-D, shC sLuc = control silencing retroviral hairpin vector and
luciferase silencing lentiviral hairpin vector; shTiam shLuc = Tiam1 and luciferase silencing hairpins; shTiam shOPN = Tiam1 and OPN silencing
hairpins. e–h Inhibition with OPN antibody. Results of mixed cell co-cultures established as in Fig. 1a with SUM1315 breast cancer cells and
either control (shC) or Tiam1-deficient (shTiam) fibroblasts, incorporating IgG or OPN antibody as indicated. e Number of projections/spheroid.
At least 180 spheroids were counted for each condition; results represent duplicate experiments. f Transwell migration of SUM1315 after isolation from
mixed cell spheroid co-cultures with indicated mammary fibroblasts. Cell counts were averaged across nine high-power fields. g SUM1315 breast cancer
cells isolated from 3D co-cultures with indicated mammary fibroblasts were cultured at low density under ultra-low adherence conditions
and tumorspheres were quantitated under light microscopy. h Populations of SUM1315 breast cancer cells were quantified by flow cytometry for
expression of indicated cell surface markers using fluorophor-conjugated antibodies after isolation from 3D co-cultures with indicated fibroblasts. For
b, c, d, f, g, and h results represent duplicate experiments, each with biologic triplicates
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Discussion
We have previously shown that silencing the Rac ex-
change factor Tiam1 in tumor-associated fibroblasts in-
duces increased invasion and metastasis in epithelial and
cancer cells, using different tissue models with a range
of technical complexity and biologically relevant tissue
context. Here we investigate the underlying mechanism
in a breast cancer-oriented system, using a novel method
for isolating human breast cancer cells out of 3D spheroid
co-cultures containing mammary fibroblasts. Co-culture of
human breast cancer cells with Tiam1-deficient fibroblasts
induces increased cancer cell invasion into matrix, while
co-culture with Tiam1-overexpressing fibroblasts induces
decreased invasion. Strikingly, breast cancer cells isolated
from 3D culture with Tiam1-deficient fibroblasts exhibit
persistent increases in migration, EMT, and cancer stem
cell characteristics. In contrast, breast cancer cells exposed
to Tiam1-overexpressing fibroblasts and then isolated from
3D co-cultures persistently display the opposite phenotypes.
The observed changes in the SUM1315 breast cancer cells
in our system are dependent on fibroblast-produced OPN,
as OPN silencing or antibody-mediated inhibition abro-
gates the increased invasion, migration, and cancer stem
cell properties induced by Tiam1-deficient fibroblasts.
Treatment of co-cultures by chemotherapeutic agents does
not prevent effects induced by Tiam1-deficient fibroblasts.
In contrast, treatment of co-cultures by the OPN inhibitor
Agelastatin A reverses all effects induced by Tiam1-
deficient fibroblasts, and notably blocks subsequent devel-
opment of lung metastases in the mouse xenograft model.
Finally, in human breast cancer samples Tiam1 expression
is significantly decreased in fibroblasts associated with inva-
sive human breast cancers compared to fibroblasts associ-
ated with ductal carcinoma in situ (DCIS). Conversely,
OPN expression is significantly increased in fibroblasts
associated with invasive breast cancers compared to fibro-
blasts associated with DCIS, suggesting the relevance of
fibroblast Tiam1 and OPN expression to the behavior of
human breast cancers.
Our results suggest several corollary findings. The
effects of the fibroblasts on the co-cultured cancer cells
are long-lived rather than transient and do not require
ongoing exposure to the fibroblasts, since changes in
post-co-culture cells persist for many weeks in vitro and
the results in vivo shown in Table 1 represent effects on
cancer stem cell populations manifesting several months
after isolation from co-culture with fibroblasts. This sug-
gests that the mechanism for these effects is more likely
to depend on changes in gene expression (such as epi-
genetic alterations), rather than changes in signaling
pathways per se. Active investigation of the underlying
mechanism is underway. In addition, the fact that the
OPN inhibitor Agelastatin A blocked SUM1315 lung
metastasis but not primary tumorigenesis in mouse
xenografts established with isolated post-co-culture
cancer cells is consistent with our earlier report that
co-implantation of breast cancer cells with Tiam1-
deficient fibroblasts affected metastasis but not pri-
mary tumorigenesis [28]. This strongly suggests a role
for fibroblast Tiam1-OPN pathway in regulating breast
Fig. 5 Effect of Agelastatin A treatment of co-cultured breast cancer cells on development of lung metastases in a mouse xenograft model. Percent of
xenograft-bearing mice with indicated degree of detectable lung metastases after implantation with SUM1315 breast cancer cells isolated from co-cultures
with indicated fibroblasts and incorporation of AgelA or MeOH at equivalent dilution in the cultures. Mean tumor weights +/- standard deviation (SD) are
indicated for each cohort. * = p< 0.5 by Fisher’s exact test
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cancer metastasis specifically. Finally, the model of ortho-
topic xenograft implantation of cancer cells isolated from
fibroblast co-culture leads to established metastatic dis-
ease more rapidly (less than 8 weeks) than orthotopic
mixed cell (fibroblast-cancer cell) implantation (20 weeks),
which may allow more practicable future study of factors
affecting tumor metastasis in vivo.
How Tiam1 expression might regulate OPN expression
is not clear. Tiam1 participates in multiple signaling path-
ways with diverse Rac effector proteins, many of which are
mediated through Tiam1 interaction with diverse scaffold-
ing proteins responding to cell-context specific signals
[40]. Whether the link to OPN regulation is through one
of the known Tiam1 pathways or an undiscovered pathway
has yet to be determined. Regulation of the promoter-
driven expression of OPN is quite complex, with multiple
contributing promoter polymorphisms and cis-regulatory
elements (reviewed in [31, 41]). Of note, Tiam1 directly
interacts with activated Ras through a Ras-binding domain
and has also been identified as a target of Wnt signaling
[14], suggesting two potential areas of overlap with known
OPN regulators for further study.
In addition, the OPN gene (also known as SPP1) has
alternative start sites and the OPN protein undergoes ex-
tensive post-translational modification, including phosphor-
ylation, glycosylation and proteolytic cleavage, leading to
complex effects. Various forms of OPN are secreted from
multiple cell types, both malignant and non-malignant.
Isoform and post-translational modification changes
are cell-type specific, but not necessarily cancer-specific
[42]. Most reports on stromal OPN center on macrophage-
derived OPN. There are limited reports of the effect of
fibroblast-derived OPN in disease. Senescent fibroblasts,
like cancer-associated fibroblasts, stimulate neoplastic and
preneoplastic cell growth [43–45]. In preneoplastic human
keratinocytes, this depended on keratinocyte MAPK activa-
tion due to dermal fibroblast OPN secretion [45, 46]. A
microdialysis-proteomics study of the mammary tumor
microenvironment in PyVmT transgenic mice identified
OPN in tumor-associated fibroblasts as well as tumor cells,
Fig. 6 Expression patterns of Tiam1 and OPN in breast cancer-associated fibroblasts, correlated with invasiveness. Representative sections of non-
invasive (DCIS) and invasive breast cancers showing tumor cells (T) with interspersed stroma (S), stained with hematoxylin and eosin (H&E), Tiam1
antibody, or OPN antibody as indicated. a and b White arrows indicate fibroblast nuclei in stroma adjacent to tumor cells. c and f Green arrows
indicate fibroblasts with detectable overexpression of indicated protein. d and e Red arrows indicate fibroblasts without overexpression of
indicated protein. All images taken at 40× magnification, scale bar indicates 100 μM
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and recombinant OPN stimulated proliferation of PyVmT
carcinoma cells in vitro [47]. Which form of OPN might be
operating in tumor-associated fibroblasts, and how effects
of fibroblast-derived OPN differ from tumor-derived OPN,
are not yet fully understood.
In experimental systems, cancer-associated fibroblasts
(CAF) are heterogeneous, suggesting several subsets within
the broad umbrella of the CAF label (reviewed in [48, 49]).
Recent reports suggest that tumor-derived OPN induces
expression of CAF-associated markers in mesenchymal
stromal cells through upregulation of transforming growth
factor beta 1 (TGF-β1) [50, 51]. Another study showed that
tumor-derived OPN has a key role in reprogramming nor-
mal mammary fibroblasts to an inflammatory CAF-like
phenotype, and found evidence of autocrine OPN effects
within the induced CAFs themselves [52]. A study of B16
mouse melanoma engineered to express platelet-derived
growth factor (PDGF) showed that tumor-derived PDGF
induces CAF recruitment and OPN expression in a subset
of recruited CAFs [53]. A search of the Oncomine database
(www.oncomine.org) identifies widely variable changes in
SPP1 expression across a wide range of tumor cell-related
data sets, but the three datasets focusing specifically on
breast cancer stroma demonstrate changes supporting our
hypothesis. In the Karnoub breast data set, SPP1 expres-
sion was 16-fold higher in the stroma of invasive ductal
breast cancers (n = 7) compared with normal breast
stroma (n = 15), with p = 2.875E-5 [54]. In the Finak
breast data set, invasive breast cancers with recurrence
over 3 years (n = 59) showed fourfold increase in SPP1
compared with normal (n = 6), with p = 1.06E-4 [55].
Conversely, in the Ma data set there was no significant
change in SPP1 in DCIS-associated stroma compared
with normal [56]. Of note, none of these data sets found
significant changes in Tiam1 expression, which may indi-
cate a post-translational mechanism for Tiam1 downregu-
lation in the tumor microenvironment [18, 20].
While there have been striking advances in the manage-
ment of early stage breast cancers, the same is not true for
metastatic breast cancer, and the death rate from metastatic
breast cancer has not changed significantly over decades.
At present, treatments for metastatic breast cancer involve
therapies based on the traditional model of reducing tumor
cell bulk, either by inducing general cytotoxic effects on the
cells or targeting specific pathways in cancer cells that lead
to bulk cell death. Current understanding in cancer biology
includes the concept of cancer stem cell populations, which
often comprise a very small percent of the primary tumor
bulk but a large percent of the cells giving rise to relapse
and metastasis. Cancer stem cell populations are relatively
resistant to traditional therapeutic approaches and may be
a key mechanism underlying dormancy in breast cancers,
leading to late metastatic relapses years after apparent
successful treatment of primary tumors. There are early
suggestions that in some systems, notably glioma and colon
cancer, OPN may promote stem-cell like changes through
triggering expression and signaling of its cell surface recep-
tor CD44 [57, 58]. These are consistent with our findings
that inhibiting OPN in tumor-associated fibroblasts dimin-
ishes cancer stem cell populations and blocks metastatic
potential in an aggressive breast cancer line.
Finally, while our experimental results were derived
largely with aggressive breast cancer cell lines that do not
express estrogen or progesterone receptors, we found that
the expression pattern of Tiam1 and OPN in human
breast cancer-associated fibroblasts was correlated with
invasiveness rather than hormone receptor expression.
Most of the human breast cancer samples we studied had
at least some expression of ER and/or PR, consistent with
the pattern of breast cancers seen in clinical practice.
Study of larger sample size will be required to fully explore
whether the Tiam1-OPN expression patterns we have ob-
served are limited to the stroma around particular breast
cancer subsets, or whether this is a general characteristic
across multiple breast cancer subsets. Furthermore, fibro-
blasts associated with human breast cancers are likely
comprised of heterogeneous cell populations, like experi-
mentally derived CAFs and breast cancer cells themselves.
It may be that the fibroblast Tiam1-OPN pathway is most
relevant in vivo in specific fibroblast subsets. Our findings
using immortalized mammary fibroblasts and specific
breast cancer cell lines lay the foundation for studying
these questions in broader contexts.
Conclusions
In summary, our results suggest that regulated Tiam1
expression in breast cancer-associated fibroblasts modu-
lates breast cancer invasion, EMT, cancer stem cell pop-
ulations, and metastasis through regulation of fibroblast
OPN secretion. At least some human breast cancers
demonstrate commensurate changes in fibroblast Tiam1
and OPN expression correlating with invasiveness. This
suggests that the fibroblast Tiam1-OPN pathway may
offer both novel therapeutic targets as well as novel bio-
markers in the treatment of metastatic breast cancer.
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